Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design and MinION testing of a nanopore targeted gene sequencing panel for chronic lymphocytic leukemia
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-01
DOI
10.1038/s41598-018-30330-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nanopore sequencing technology and tools for genome assembly: computational analysis of the current state, bottlenecks and future directions
- (2018) Damla Senol Cali et al. BRIEFINGS IN BIOINFORMATICS
- Nanopore sequencing and assembly of a human genome with ultra-long reads
- (2018) Miten Jain et al. NATURE BIOTECHNOLOGY
- Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients
- (2018) Cosimo Cumbo et al. Oncotarget
- Mutational analysis in BCR - ABL1 positive leukemia by deep sequencing based on nanopore MinION technology
- (2017) Crescenzio F. Minervini et al. EXPERIMENTAL AND MOLECULAR PATHOLOGY
- What is the potential of nanolock– and nanocross–nanopore technology in cancer diagnosis?
- (2017) Li-Qun Gu et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons
- (2017) Ana E. Rodríguez-Vicente et al. Oncotarget
- Development and preliminary evaluation of a multiplexed amplification and next generation sequencing method for viral hemorrhagic fever diagnostics
- (2017) Annika Brinkmann et al. PLoS Neglected Tropical Diseases
- de novo assembly and population genomic survey of natural yeast isolates with the Oxford Nanopore MinION sequencer
- (2017) Benjamin Istace et al. GigaScience
- Nanolock–Nanopore Facilitated Digital Diagnostics of Cancer Driver Mutation in Tumor Tissue
- (2017) Yong Wang et al. ACS Sensors
- Present and future of personalized medicine in CLL
- (2016) Emili Montserrat et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Nanopore sequencing detects structural variants in cancer
- (2016) Alexis L. Norris et al. CANCER BIOLOGY & THERAPY
- TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
- (2016) Crescenzio Francesco Minervini et al. Diagnostic Pathology
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Coming of age: ten years of next-generation sequencing technologies
- (2016) Sara Goodwin et al. NATURE REVIEWS GENETICS
- Droplet digital PCR analysis of NOTCH1 gene mutations in chronic lymphocytic leukemia
- (2016) Angela Minervini et al. Oncotarget
- NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation
- (2015) F Pozzo et al. LEUKEMIA
- De novo sequencing and variant calling with nanopores using PoreSeq
- (2015) Tamas Szalay et al. NATURE BIOTECHNOLOGY
- A complete bacterial genome assembled de novo using only nanopore sequencing data
- (2015) Nicholas J Loman et al. NATURE METHODS
- Improved data analysis for the MinION nanopore sequencer
- (2015) Miten Jain et al. NATURE METHODS
- Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution
- (2015) L.-A. Sutton et al. HAEMATOLOGICA
- Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
- (2014) A. Martinez-Trillos et al. BLOOD
- Recurrent mutations refine prognosis in chronic lymphocytic leukemia
- (2014) P Baliakas et al. LEUKEMIA
- SF3B1 mutations in chronic lymphocytic leukemia
- (2013) Y. Wan et al. BLOOD
- Error analysis of idealized nanopore sequencing
- (2013) Christopher R. O'Donnell et al. ELECTROPHORESIS
- Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
- (2012) H. Thorvaldsdottir et al. BRIEFINGS IN BIOINFORMATICS
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
- (2012) D. C. Koboldt et al. GENOME RESEARCH
- NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia
- (2012) L Mansouri et al. LEUKEMIA
- Molecular genetics of high-risk chronic lymphocytic leukemia
- (2012) Davide Rossi et al. Expert Review of Hematology
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
- (2011) D. Rossi et al. BLOOD
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
- (2011) D. Rossi et al. BLOOD
- Decreased TET2 gene expression during chronic myeloid leukemia progression
- (2011) F. Albano et al. LEUKEMIA RESEARCH
- Integrative genomics viewer
- (2011) James T Robinson et al. NATURE BIOTECHNOLOGY
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms
- (2010) I. M. Carr et al. JOURNAL OF MEDICAL GENETICS
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
- (2010) K. Wang et al. NUCLEIC ACIDS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More